Background: A number of randomized controlled trials (RCTs) have reported improvement in breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the initial five years after diagnosis. However, the toxicity profile of extended AIs is uncertain. Methods: We identified RCTs that compared extended AIs to placebo or no treatment using MEDLINE and a review of abstracts from key conferences between 2013 and 2016. Odds ratios (ORs), 95% confidence intervals (CIs), absolute risks, and the number needed to harm (NNH) were computed for prespecified safety and tolerability outcomes including cardiovascular events, bone fractures, second cancers (excluding new breast cancer), treatment discontinuation for adverse events, and death without recurrence. All statistical tests were two-sided. Results: Seven trials comprising 16 349 patients met the inclusion criteria. Longer treatment with AIs was associated with increased odds of cardiovascular events (OR ¼ 1.18, 95% CI ¼ 1.00 to 1.40, P ¼ .05, NNH ¼ 122), bone fractures (OR ¼ 1.34, 95% CI ¼ 1.16 to 1.55, P < .001, NNH ¼ 72), and treatment discontinuation for adverse events (OR ¼ 1.45, 95% CI ¼ 1.25 to 1.68, P < .001, NNH ¼ 21). Longer treatment with AIs did not influence the odds of either second malignancy (OR ¼ 0.93, 95% CI ¼ 0.73 to 1.18, P ¼ .56) or deaths without breast cancer recurrence (OR ¼ 1.11, 95% CI ¼ 0.90 to 1.36, P ¼ .34). Conclusions: Extended treatment with AIs is associated with an increased risk of cardiovascular events and bone fractures. There is no statistically significant increase in deaths without breast cancer recurrence among patients receiving longer treatment with AIs. These data should be taken into account when considering extended adjuvant AIs.
limited. The impact of safety and tolerability is likely of greater importance for extended adjuvant therapy compared with treatment in the initial five years because the absolute risk of breast cancer recurrence falls with time (18) while with increasing age, the baseline risk of morbidity and mortality from other illnesses rises (19) . As such, robust data on the toxicity of extended adjuvant therapy are desirable in order to appropriately counsel patients and provide optimal recommendations on continuation of adjuvant therapy beyond five years.
Here, we report on a meta-analysis evaluating adverse events reported in phase III randomized controlled trials (RCTs) comparing extended treatment with AIs to placebo or no treatment in postmenopausal women with hormone receptorpositive early breast cancer.
Methods

Literature Review and Study Identification
A literature search utilizing MEDLINE (host: OVID; 1996-December week 3, 2016) and databases for the Annual Meetings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium between 2013 and 2016 was undertaken. The search was restricted to English language articles. The terms "adjuvant," "aromatase inhibitor," "tamoxifen," and "breast cancer" and similar terms were crosssearched by using the following search algorithm: ((aromatase inhibitor OR anastrozole OR letrozole OR exemestane) AND (tamoxifen) AND (adjuvant) AND (breast neoplasm MeSH OR ((breast OR mammary) AND (carcinoma OR malignan* OR neoplasm OR tumor)))) AND (randomized controlled trial [ [mh] ). Eligible trials included all phase III RCTs comparing longer duration of AI therapy with placebo or no treatment following initial adjuvant endocrine therapy with either tamoxifen, AIs, or both in postmenopausal women. We utilized a hierarchal primary data source. Data from safety analyses were preferred, and, when not available, data from intention-to-treat analyses were utilized instead.
Data Extraction
Data on potentially life-threatening adverse events of any grade as reported in individual trials were extracted. Collected data included the number of patients with the following prespecified adverse events: cardiovascular events, bone fractures, and secondary malignancies (excluding second primary breast cancers), as well as the total number of patients at risk of each adverse event. These events were chosen because they are associated with substantial morbidity and mortality, are commonly reported in RCTs, and are less prone to reporting bias. Data on symptomatic adverse events unlikely to be associated with mortality, such as arthralgia and genitourinary atrophy, were not considered. Additionally, data regarding treatment discontinuation for adverse events, as well as deaths without breast cancer recurrence, were collected. Finally, we collected data reporting both disease-free and overall survival from each study. Data were extracted independently by two reviewers (HG and EA). Discrepancies were resolved by consensus. All data were extracted from primary publications, their associated online appendices, or from the conference presentation if the study was not published in full.
Data Synthesis and Statistical Analysis
The primary analysis compared the odds of adverse events between patients who were randomly assigned to prolonged treatment with AIs and those randomly assigned to placebo or no treatment. Data from individual studies were pooled in a metaanalysis. The odds ratios (ORs) and associated 95% confidence intervals (CIs) were computed for all adverse events and were then pooled in a meta-analysis using RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). Pooled estimates of odds ratio were computed using the Mantel-Haenszel odds ratio method (21) . Due to substantial clinical heterogeneity between studies in the time from diagnosis to random assignment and in exposure to prior treatments, analyses were performed using random effects modeling irrespective of the statistical heterogeneity. Statistical heterogeneity was reported using Cochran Q (which assesses whether observed differences in results are compatible with chance alone) and I 2 statistics (which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error). Statistically significant heterogeneity was defined as a Cochran Q P value of less than .10 or I 2 greater than 50%. Absolute risks were calculated as the number of events per person over the follow-up period of individual trials. The difference in absolute risk between the prolonged treatment and control groups was also presented as the number needed to harm (NNH), which quantifies the number of patients who would need to be treated with longer duration of AIs to cause an adverse event in one patient who would not otherwise have experienced the adverse event. Metaregression was used to explore the influence of median age at random assignment, duration of follow-up, and prior treatments on the odds ratio for each adverse event. Metaregression comprised a univariable linear regression weighted by individual study sample size exploring the association between median age, duration of follow-up, and proportion of patients treated with prior tamoxifen, AIs, or cytotoxic chemotherapy on the log of the odds ratio for each adverse event.
Meta-regression was performed using SPSS version 21 (IBM Corp, Armonk, NY) using the weighted least squares (mixed effect) function (44) . Finally, in an exploratory analysis, we pooled the disease-free and overall survival from each trial using inverse variance and random effects modeling. Statistical tests were two-sided, and statistical significance was defined as a P value of less than .05.
Results
Included Studies
Our search identified 1546 studies initially. After exclusions, we identified 14 individual RCTs evaluating adjuvant endocrine monotherapy. Of these, seven trials explored initial adjuvant therapy. Therefore, seven studies were eligible for analysis (see Figure 1 ). Eligible studies comprised 16 349 patients. Individual study characteristics are shown in Table 1 while an individual study schema is shown in Supplementary Figure 1 (available online). Four trials (MA.17R [12] , MA17 [13] , NSABP B33 [23] , and NSABP B42 [24] ) compared five years of extended AIs with placebo. One trial (ABCSG 6a [11] ) compared three years of extended anastrozole with no treatment, and two trials (DATA [25] and IDEAL [26] ) compared longer with shorter duration of AIs. In three of these trials (13, 23, 25) , eligibility required no prior exposure to AIs; however, in one trial (ABCSG 6a [11] ) patients were not exposed to third-generation AIs, but approximately half of the cohort had been treated with aminoglutethimide, a first-generation AI. Adverse events were defined differently in each trial (see Table 2 ).
Cardiovascular Events
Six studies reported data on cardiovascular events (11) (12) (13) (24) (25) (26) . Prolonged therapy with AIs was associated with a statistically significant increase in odds of cardiovascular events (OR ¼ 1.18, 95% CI ¼ 1.00 to 1.40, P ¼ .05) (see Figure 2A ). There was no evidence of statistically significant heterogeneity (Cochran Q P ¼ .21, I 2 ¼ 30%). In absolute terms, 7.0% of patients in the prolonged AIs group had cardiovascular events, compared with 6.0% of patients in the control group. The weighted pooled absolute difference was 0.8%, with a NNH of 122 (see Table 3 ). Results of meta-regression are shown in Table 4 . There was no association between the relative odds of cardiovascular events and median age at random assignment, median duration of follow-up, or the proportion of patients who had received prior tamoxifen or prior AIs. Hypertension was reported in only three studies (12, 13, 26) . There was no association between longer duration of AIs and increased odds of hypertension (OR ¼ 1.02, 95% CI ¼ 0.86 to 1.21, P ¼ .82; data not shown). There was no evidence of statistically significant heterogeneity (Cochran Q P ¼ .42, I
2 ¼ 0%). In absolute terms, hypertension was reported in 7.3% of patients receiving longer treatment with AIs and 7.1% of patients in the control group. The weighted pooled absolute difference was 0.1%, with a NNH of 770.
Bone Fractures
All seven studies reported data on bone fractures (11) (12) (13) (23) (24) (25) (26) . Prolonged therapy with AIs was associated with statistically significantly increased odds of bone fractures (OR ¼ 1.34, 95% CI ¼ 1.16 to 1.55, P < .001) (see Figure 2B ). There was no evidence of statistically significant heterogeneity (Cochran Q P ¼ .38, I 2 ¼ 6%). In absolute terms, fractures occurred in 6.3% of the prolonged AI group and 4.8% in the control group, with a weighted pooled absolute difference of 1.4% and a NNH of 72 (see Table 3 ).
Results of the meta-regression are shown in Table 4 . There was no association between the relative odds of bone fracture and
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Second Cancers
Four trials reported the occurrence of second malignancies excluding breast cancer, three studies reported on all second malignancies (23) (24) (25) , and one study reported only on endometrial cancer (13) . Pooled data showed that prolonged treatment with AIs was not associated with second cancers (OR ¼ 0.93, 95% CI ¼ 0.73 to 1.18, P ¼ .56) (see Figure 2C ). There was no evidence of statistically significant heterogeneity (Cochran Q P ¼ . Table 4 . There was no association between the relative odds of second cancers and median age at random assignment, median duration of follow-up, or the proportion of patients who had received prior tamoxifen, prior AIs, or prior chemotherapy.
Discontinuation for Adverse Events
Discontinuation of treatment for adverse events was reported in six studies (11) (12) (13) (24) (25) (26) . Pooled data showed that longer duration of treatment with AIs was associated with a 45% increased odds for treatment discontinuation for adverse events compared with placebo or no treatment (OR ¼ 1.45, 95% CI ¼ 1.25 to 1.68, P < .001) (see Figure 2D ). There was evidence of statistically significant heterogeneity (Cochran Q P ¼ .07, I 2 ¼ 51%).
In absolute terms, discontinuation for adverse events occurred in 17.0% of patients in the prolonged treatment group and 13.4% in the control group. The weighted pooled absolute difference was 4.8%, with a NNH of 21. There was no association between the relative odds of discontinuation for adverse events and median age at random assignment, median duration of follow-up, or proportion of patients who had received prior tamoxifen or prior AIs (see Table 4 ).
Death Without Recurrence
Death without breast cancer recurrence was reported in five studies (11) (12) (13) 22, 23) . There was no statistically significant association between death without breast cancer recurrence and longer use of AIs (OR ¼ 1.11, 95% CI ¼ 0.90 to 1.36, P ¼ .34) (see Figure 2E ). There was no evidence of statistically significant heterogeneity (Cochran Q P ¼ .44, I 2 ¼ 0%). In absolute terms, 3.3%
of the patients treated with prolonged AIs and 2.9% of those treated with placebo or no treatment died without breast cancer recurrence. The weighted pooled absolute difference was 0.3%, with a NNH of 371. There was no association between the relative odds of death without breast cancer recurrence and median age at random assignment, median duration of follow-up, or the proportion of patients who had received prior tamoxifen or prior AIs (see Table 4 ).
In an exploratory analysis, despite improvement in diseasefree survival (pooled OR ¼ 0.78, 95% CI ¼ 0.68 to 0.88, P< .001) (see Supplementary Figure 2 , available online), no effect on overall survival was observed (OR ¼ 1.01, 95% CI ¼ 0.89 to 1.14, P ¼ .92) (see Supplementary Figure 2 , available online).
Discussion
Late relapse, which can occur decades after initial diagnosis, is a hallmark of hormone receptor-positive early breast cancer (1). Consequently, there has been interest in extended adjuvant therapy in such patients. The net benefit of any therapy is comprised of the balance between benefits and risks. In the setting of extended adjuvant endocrine therapy, an accurate assessment of this balance is essential because over time the risk of breast cancer recurrence and death falls and the contribution of concurrent illnesses to morbidity and mortality increases (19) . As such, knowledge of the potential impact of extended anticancer therapy on comorbidities is important.
Typically, individual trials of adjuvant endocrine therapy are designed to evaluate efficacy. Most have limited power to explore toxicities, especially those that are less common. As a result, pooling of data from multiple trials is valuable to evaluate accurately the effect of adjuvant therapy on safety and tolerability. An example of this was the observation of increased cardiovascular disease with AIs relative to tamoxifen as initial adjuvant therapy. No effect was seen in individual trials, but a modest increase in cardiovascular disease was observed in a meta-analysis of randomized trials (15) . In contrast, populationbased studies that utilized different definitions of cardiovascular events have reported conflicting data (19, 28) . Most of the current knowledge on the safety and tolerability of AIs is derived from data that compared AIs with tamoxifen. Consequently, the influence of extended AIs on toxicity when compared with no treatment is uncertain.
There has been increasing interest in the potential interaction of AIs on cardiovascular disease. Cardiovascular disease and breast cancer share a number of risk factors (29, 30) , and, thanks to effective breast cancer therapy, the most common cause of death among women with early breast cancer is cardiovascular disease (31, 32) . Data from trials of initial adjuvant therapy have shown that longer duration of AIs is associated with increased cardiovascular events (15) . A key limitation of these data is that in all trials the comparison group was tamoxifen and it was not possible to determine if the relative increase in the odds of cardiovascular events was related to a real increase in risk with AIs or some protection from tamoxifen (33) . Recent data focusing on studies of AIs compared with placebo or no treatment suggested no increase in risk of cardiovascular events with AIs (34). However, this study did not include a number of the large randomized trials reported recently. In the current study, we observed a statistically significant increase in the odds of cardiovascular events with longer durations of AIs. The relative increase was modestly lower in magnitude to that observed in the initial adjuvant setting (OR ¼ 1.18 vs 1.26, respectively); however, because of higher event rates in this older population of patients with lower competing risks of cancer death, this relative increase translated to a similar absolute risk (NNH ¼ 122 vs 132, respectively). There are concerns that safety and tolerability data from clinical trials underestimate the effect of toxicity when treatment is administered to patients outside of clinical trials. Data show that many patients in routine practice do not meet the eligibility criteria of clinical trials (35) . Eligibility criteria of randomized trials often exclude patients with preexisting cardiovascular disease (36) , a group at higher risk of treatmentrelated toxicity. A population-based observation study focusing on cardiovascular events rather than a composite of both cardiovascular and cerebrovascular events reported that, compared with tamoxifen, AIs are associated with a doubling in the hazard of serious cardiovascular events (37), a magnitude of effect much greater than observed in clinical trials.
The mechanism of effect of AIs on cardiovascular morbidity is not clear. AIs have been associated with an increase in cardiovascular risk factors such as dyslipidemia and arterial hypertension (15, 38, 39 ). In the current study, we observed a similar risk of incident arterial hypertension among those receiving longer therapy with AIs and control groups. This suggests that the link between AIs and cardiovascular events may relate to mechanisms independent of arterial hypertension such as accelerated atherosclerosis, an observation reported elsewhere (40) .
In postmenopausal women, AIs cause accelerated bone loss (1). Several trials of initial adjuvant therapy showed a statistically significantly higher risk of bone fractures in patients treated with AIs compared with tamoxifen (4, (41) (42) (43) . Again, this analysis was potentially confounded by a protective effect of tamoxifen. In the current study, the detrimental effect on bone health was confirmed, with a 34% increased odds of developing bone fractures with AIs compared with placebo or no treatment. This increase translated to a NNH of 72, modestly higher than data observed in the initial adjuvant setting (NNH ¼ 46) (15) . Potential reasons for the lower magnitude of absolute risk of bone fractures with extended AI therapy compared with initial adjuvant therapy are the protective effect of tamoxifen in the initial adjuvant setting, improved screening of patients treated with AIs with bone mineral density scans, and the treatment of those at risk with antiresorptive therapies. The impact of treatment-related bone loss may be attenuated in the future with the increasing use of adjuvant bone-targeted therapy, even in those without preexisting or treatment-related bone loss (44) .
Statistically significantly more patients randomly assigned to prolonged treatment with AIs discontinued therapy for adverse events. Pooled data showed that for every 21 patients assigned to longer therapy with AIs, one patient discontinued treatment due to adverse events. This finding is notable because all enrolled participants had received three to 10 years of prior endocrine therapy prior to random assignment, suggesting that serious toxicity necessitating discontinuation of therapy can occur even at a late stage of treatment. All P values are two-sided. CI ¼ confidence interval; OR ¼ odds ratio.
REVIEW
Extended adjuvant AIs are associated with a 20% to 25% relative reduction in disease recurrence, although in many cases such events are comprised of local or contralateral in-breast recurrences. In our analysis, we observed a numerical excess of deaths without breast cancer recurrence with prolonged AI therapy; however, this association was not statistically significant. This finding may explain why there is no apparent effect of extended therapy with AIs on overall survival. The increased number of noncancer deaths with longer treatment with AIs attenuates the contribution of reduced breast cancer deaths to overall survival. It is important to stress that overall survival data were immature in many studies and it is possible that the long-term effect of exposure to AIs may result in the emergence of both a survival advantage and additional adverse events with longer durations of follow-up.
Of interest, we did not identify any factors that influenced the effect of prolonged treatment with AIs on safety and tolerability. Similar magnitudes of relative odds were observed for all adverse events of interest, irrespective of age, duration of follow-up, or prior treatments (including tamoxifen, AIs, and chemotherapy). These findings do not exclude an effect on absolute risk. Cardiovascular events and bone fractures increase with age. As such, despite no effect on the relative risk of these events between prolonged treatment with AIs and control, it is anticipated that older patients and those with more comorbidities with longer durations of AIs will have a higher absolute risk of adverse events than those treated with placebo or no treatment.
This study has limitations. First, this is a literature-based rather than an individual patient-based meta-analysis. Consequently, data on comorbidities and concurrent medications were not available and could not be adjusted for in the analysis. Additionally, because data were extracted from reports of trials with different durations of follow-up, we were unable to report actuarial rates of toxicity. Second, the reporting and definition of toxicity was variable among the different trials and REVIEW may lead to some uncertainty about estimates of odds of adverse events. Furthermore, one study (11) was open label rather than placebo controlled and therefore subject to ascertainment bias. Third, although the grade of the toxicity might clarify the severity of the adverse event on the patient, grading of adverse events was not reported uniformly, and therefore our analysis included all grades of toxicity. Fourth, inclusion criteria for each trial were different, especially with regard to prior adjuvant endocrine therapy. Some patients received only two to three years of prior tamoxifen (24) , while others received up to 10 years of endocrine therapy with both tamoxifen and AIs (12) , making the included patients in this meta-analysis heterogeneous. Finally, toxicity reporting is usually collected only until an efficacy event of interest occurs. As the majority of women with hormone receptor-positive breast cancer survive for several years even with metastatic disease, the impact of adverse events after recurrence remains of interest.
In conclusion, extended treatment with AIs is associated with an increased risk of cardiovascular events and bone fractures. There is no statistically significant excess of deaths without breast cancer recurrence among patients receiving longer durations of AIs. These data should be taken into account when considering extended adjuvant AIs for breast cancer patients, especially patients with preexisting comorbidities or risk factors thereof.
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